Is circulating tumor cell count-driven cost-effective for first-line therapy choice in HR+/HER2- metastatic breast cancer in the United States?

CONCLUSIONS: The findings of this cost-effectiveness analysis suggest that, at the current price of CTC enumeration, choosing first-line treatment options based on CTC count is a cost-effectiveness approach for treating patients with HR+/HER2- MBC in the US.PMID:38359563 | DOI:10.1016/j.breast.2024.103680

Source: Breast - February 15, 2024 Category: Cancer & Oncology Authors: Huiting Lin Wenhua Wu Xiaoya Lou Yiming Wang Hong Sun Jiaqin Cai Suyan Liu Xiaoxia Wei Source Type: research